NANO MRNA Co.,Ltd. (3NQ.F)

0.7800 +0.0100 (+1.30%) At close: 05:15PM CEST

NANO MRNA Co.,Ltd.

Atago Green Hills MORI Tower
26th Floor 2-5-1 Atago Minato-ku
Tokyo
Japan
81 3 6432 4791
https://www.nanomrna.co.jp

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 17

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Atsushi Matsumura	Executive Chairman of the Board	N/A	N/A	1962
Dr. Shiro Akinaga Ph.D.	President, CEO, CSO, MD of R&D Division and Director	N/A	N/A	1956
Mr. Koji Fujimoto	CFO, MD of Corporate Division & Director	N/A	N/A	1972

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company's pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers Complex, an antibacterial ear drops; cosmetic raw material, and platelet-rich therapy. The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co.,Ltd. in June 2023. NANO MRNA Co.,Ltd. was incorporated in 1996 and is headquartered in Tokyo, Japan.

Corporate governance

NANO MRNA Co.,Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.